Gary M Studnicka

US Patent:

6649742, Nov 18, 2003

Filed:

Nov 13, 2000

Appl. No.:

09/711485

Inventors:

Marc D. Better - Los Angeles CA
Stephen F. Carroll - Walnut Creek CA
Gary M. Studnicka - Santa Monica CA

Assignee:

XOMA Technology Ltd.

International Classification:

C07K 1600

US Classification:

5303873, 530866

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

7153932, Dec 26, 2006

Filed:

Nov 18, 2003

Appl. No.:

10/717243

Inventors:

Marc D. Better - Los Angeles CA, US
Stephen F. Carroll - Walnut Creek CA, US
Gary M. Studnicka - Santa Monica CA, US

Assignee:

Research Development Foundation - Carson City NV

International Classification:

C07K 16/00
A61K 38/16
A61K 38/10
C12P 21/08

US Classification:

530326, 530350, 5303873, 530866

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

20030229207, Dec 11, 2003

Filed:

Jan 10, 2003

Appl. No.:

10/340189

Inventors:

Gary Studnicka - Santa Monica CA, US

Assignee:

XOMA Technology Ltd.

International Classification:

A61K039/395
C07K016/28

US Classification:

530/387100, 530/388220, 424/144100

Abstract:

Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.

US Patent:

20040005630, Jan 8, 2004

Filed:

Dec 18, 2002

Appl. No.:

10/325696

Inventors:

Gary Studnicka - Santa Monica CA, US

Assignee:

XOMA Technology Ltd.

International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/007100, 702/019000

Abstract:

Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a hereterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.

US Patent:

20050239141, Oct 27, 2005

Filed:

May 19, 2005

Appl. No.:

11/133775

Inventors:

Gary Studnicka - Santa Monica CA, US

International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50

US Classification:

435007100, 702019000

Abstract:

Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a hereterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.

US Patent:

20110319598, Dec 29, 2011

Filed:

Dec 17, 2009

Appl. No.:

13/140554

Inventors:

Mark Christopher Evans - Pleasant Hill CA, US
Gary Studnicka - Santa Monica CA, US

Assignee:

XOMA TECHNOLOGY LTD. - Berkeley CA

International Classification:

C07K 1/14
G06F 19/10

US Classification:

5303873, 530412, 5303871, 702 19

Abstract:

The present disclosure relates to methods and materials for determining an isoelectric point for a protein including, for example, a binding molecule such as an antibody. The isoelectric points may be used in methods for the preparation of proteins. Such methods may comprise identifying amino acid residues that are exposed on the surface of the protein in a sequence of amino acid residues of the protein, assigning a pKa value to the surface exposed amino acid residues, and calculating the isoelectric point of the protein from the pKa values assigned to the surface exposed amino acid residues. The methods of the present disclosure may be used for selecting and utilizing a buffer for purification of a protein, preparing a protein formulation, purifying a protein and/or stabilizing a protein in solution.

US Patent:

58211233, Oct 13, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/477531

Inventors:

Gary M. Studnicka - Santa Monica CA

Assignee:

XOMA Corporation - Berkeley CA

International Classification:

C07H 2104
A61K 39395
C07K 1623
C07K 14725

US Classification:

435328

Abstract:

Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.

US Patent:

57701962, Jun 23, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/472788

Inventors:

Gary M. Studnicka - Santa Monica CA

Assignee:

XOMA Corporation - Berkeley CA

International Classification:

C07K 1628
C07K 14725
C07K 14705
A61K 39395

US Classification:

4241331

Abstract:

Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.